Phase I Pilot Study of Gene Therapy for Cystic Fibrosis Using Cationic Liposome Mediated Gene Transfer

The University of Alabama at Birmingham

Status and phase: Completed; Phase 1

Conditions: Cystic Fibrosis

Treatments: Genetic: pGT-1 gene lipid complex

Study type: Interventional

Funder types: Other

Identifiers

NCT00004471

199/13941

UAB-F930923001

UAB-6097

Details and patient eligibility

About

OBJECTIVES:

Determine whether copies of the cystic fibrosis gene (pGT-1) can be delivered to the cells lining the nose of cystic fibrosis patients using cationic liposome (DMRIE/DOPE) mediated gene transfer.

Full description

PROTOCOL OUTLINE: Under direct visualization, patients receive lipid/DNA formulation (pGT-1 lipid complex) by syringe instillation over 30 minutes to the right inferior nasal turbinate.

Patients are followed daily for 7 days, twice a week for 3 weeks, every 2-3 weeks for 10 weeks, then every 3 months thereafter.

Sex: All

Ages: 16+ years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

• Cystic fibrosis patients
• Not pregnant Fertile patients must use effective contraception